The following blog post is for entertainment and informational purposes only. It is not intended to provide medical advice or diagnosis. Please consult your doctor before making any health-related decisions.
"Memory research peptides" is a market label for compounds such as semax, selank and dihexa, though dihexa is not a peptide. Products sold under this label carry a "for research use only" statement, meaning they are not intended for human use. As of October 2026, semax, selank and dihexa are not approved by the FDA for human use. If you're exploring options, the safer path is to talk with a licensed provider instead of starting with a research-labeled compound.
What are memory research peptides?
"Memory research peptides" and "cognitive peptides for research" are market labels for compounds sold online with a "for research use only" statement, a labeling statement that the product is not intended for human use. Semax, selank and dihexa are three compounds discussed under these labels. Dihexa is not a peptide, although it is discussed alongside them. These are research-labeled substances, not clinical treatments.
What does "research use only" mean for peptides?
A "research use only" label is the seller's statement that a product is not intended for human use, and it is not an FDA approval. In warning letters to online peptide sellers, FDA has found that despite "research use only" or "not for human consumption" statements, evidence from the sellers' websites showed the products were intended as drugs for human use, which made them unapproved new drugs. Products sold this way are not manufactured or tested to pharmaceutical standards.
What Research Has Studied: What FDA Reports About Semax, Selank and Dihexa
| Compound | What FDA has reported | Status as of October 2026 |
|---|---|---|
| Semax | FDA was not able to find pharmacokinetic studies in humans following exposure to semax by any route of administration | Not approved by the FDA for human use |
| Selank | FDA says it lacks important information about the safety of selank in humans | Not approved by the FDA for human use |
| Dihexa (not a peptide) | FDA has not identified any human exposure data for drug products containing dihexa acetate by any route | Not approved by the FDA for human use |
The FDA statements in the table come from an advisory committee briefing document for semax and from FDA's compounding safety-risks page for selank and dihexa. They describe gaps in human information rather than study results, and human data is limited. The safety of these compounds in humans has not been established.
Regulatory status of memory research peptides as of October 2026
FDA's records on semax, selank and dihexa differ in detail. The regulatory situation is complex and may change, so check FDA.gov for current information.
Are semax, selank and dihexa FDA-approved?
As of October 2026, semax, selank and dihexa are not approved by the FDA for human use.
- Semax (not approved by the FDA for human use): FDA states that there is no applicable USP or NF monograph for semax (free base) or semax acetate and that neither is a component of a drug FDA has approved. In briefing documents for its July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that semax not be included on the 503A bulks list and said it does not intend to issue a final determination until it has considered the committee's input.
- Selank (not approved by the FDA for human use): FDA says compounded selank acetate may pose an immunogenicity risk, meaning a potential to provoke an immune response, for certain routes of administration.
- Dihexa (not a peptide; not approved by the FDA for human use): The table above contains FDA's statement on human data for dihexa.
For pharmacy compounding under section 503A of the FD&C Act, a bulk drug substance that has no applicable USP or NF monograph and is not a component of an approved drug must appear on FDA's 503A bulks list, which FDA develops through regulation. Being considered for this list, or proposed for it, is not an FDA approval.
Semax, selank acetate and dihexa acetate are listed under "Bulk drug substances nominated but withdrawn" on FDA's page of bulk drug substances that may present significant safety risks in compounding (content current as of 04/22/2026). That section covers substances that were previously on the page's main safety-risk list (category 2) and whose nominations were withdrawn by the nominators.
Risks of research-use-only products
Products sold as cognitive peptides for research share the risks of other research-labeled products.
- Purity and composition: Products labeled for research use are not manufactured or tested to pharmaceutical standards, so purity and composition can differ from what the label claims. FDA has warned that drugs that have circumvented regulatory safeguards may be contaminated or counterfeit, or may contain different ingredients altogether.
- Dose accuracy: A label or a low price tells a buyer nothing about what is actually inside. The same FDA warning notes that such drugs may contain varying amounts of active ingredients.
- Sterility: Sterility may differ from what the label claims. In a general statement about injectable drug products, FDA says they can pose risks of serious harm because they are delivered directly into the body, sometimes directly into the bloodstream, and bypass some of the body's key defenses against toxins and microorganisms.
- No medical screening: Self-use means no review of health history, current medications or other conditions before use.
- No supervision: Self-use also means there is no clinician involved if a problem occurs.
If you're considering research peptides, a conversation with a licensed Valhalla Vitality provider is a safer first step. The provider reviews health history and goals and decides whether an appropriate treatment option exists. Not everyone will qualify. Start with a conversation with a licensed provider.
What a licensed provider evaluation looks like
A research-labeled product is obtained without that evaluation. Understanding what a provider review covers can clarify the difference between self-sourcing and supervised care.
- An intake covers health history, current medications and goals.
- A licensed provider reviews the intake and decides whether any treatment option is clinically appropriate.
- Prescription medication is prescribed by a licensed provider after an evaluation and dispensed by a licensed pharmacy.
- Availability varies by state.
A safer next step
Starting with a licensed provider's evaluation is a different path than purchasing a research-labeled compound. Book Your Consultation with a Valhalla Vitality provider who reviews your health history and goals and determines whether any clinically appropriate option exists for you. No prescription is promised, and not everyone will qualify.
FAQ
What is known about the safety of memory research peptides in humans?
The safety of semax, selank and dihexa in humans has not been established. FDA says it lacks important information about the safety of selank in humans, could not find human pharmacokinetic studies for semax, and has not identified human exposure data for drug products containing dihexa acetate. Self-use of research-labeled products also means no medical screening and no clinician involved if a problem occurs.
Is dihexa a peptide?
Dihexa is not a peptide, although it is discussed alongside memory research peptides. As of October 2026, dihexa is not approved by the FDA for human use. FDA says it lacks important information about the drug's safety, including whether it would cause harm in humans.
What did FDA propose for semax in July 2026?
In briefing documents for its July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that semax not be included on the 503A bulks list. That list concerns drug compounding, not FDA approval. FDA said it does not intend to issue a final determination until it has considered the committee's input, and as of October 2026, semax is not approved by the FDA for human use.
What has FDA said about selank?
As of October 2026, selank is not approved by the FDA for human use. FDA says compounded selank acetate may pose an immunogenicity risk, meaning a potential to provoke an immune response, for certain routes of administration, and that it lacks important information about selank's safety in humans. FDA lists selank acetate under "Bulk drug substances nominated but withdrawn" on its compounding safety-risks page.
What is the difference between a research peptide and a prescribed medication?
Prescription medication is prescribed by a licensed provider after an evaluation and dispensed by a licensed pharmacy. A product sold as a research peptide is labeled "research use only," a labeling statement that it is not intended for human use, and is obtained without medical screening or supervision. Not everyone will qualify, and only a provider can decide whether any treatment is appropriate.
Sources
- U.S. Food and Drug Administration. Warning letters database (letters to online peptide sellers, 2025-2026). fda.gov
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- U.S. Food and Drug Administration. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Introduction. fda.gov
- U.S. Food and Drug Administration. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Semax. fda.gov
This article is for educational purposes only and is not medical advice. Prescription treatments are available only after evaluation by a licensed provider, and not everyone will qualify. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
You May Also Like
Research Peptides for Anti-Aging: What the Evidence Shows
Research peptides for anti-aging are sold for research use only and are not intended for human use. See what FDA records show and the safer path forward.
October 29, 2026 ETRead more →
Research Peptides for Muscle Growth: Claims vs Evidence
Research peptides for muscle growth are sold as research use only. See what human data exists and their FDA and WADA status as of October 2026.
October 29, 2026 ETRead more →
SpermidineSpermidine Benefits: Science, Safety, and How It Works
Spermidine benefits include autophagy, cardiovascular support, hair growth, and longevity support. Learn what the science shows and how to start.
October 29, 2026 ETRead more →